Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.6 NOK | 0.00% | +4.89% | -6.99% |
04-30 | Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-30 | Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024 |
Business Summary
Number of employees: 58
Sales per Business
NOK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Renal Diagnostic
41.7
%
| 40 | 39.3 % | 56 | 41.7 % | +40.92% |
Inflammation Diagnostic
38.3
%
| 43 | 42.2 % | 52 | 38.3 % | +20.72% |
Other Diagnostic
20.0
%
| 19 | 18.5 % | 27 | 20.0 % | +44.07% |
Sales per region
NOK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe
68.6
%
| 72 | 70.4 % | 93 | 68.6 % | +29.60% |
Asia
24.9
%
| 24 | 23.2 % | 34 | 24.9 % | +42.63% |
United States
6.5
%
| 6 | 6.4 % | 9 | 6.5 % | +35.10% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Hilja Ibert
CEO | Chief Executive Officer | - | 15/07/18 |
Njaal Kind
DFI | Director of Finance/CFO | 52 | 01/01/18 |
Chief Tech/Sci/R&D Officer | - | - | |
Torsten Knüttel
CTO | Chief Tech/Sci/R&D Officer | - | 04/08/19 |
General Counsel | - | - | |
Markus Jaquemar
PRN | Corporate Officer/Principal | - | - |
Jack Andreassen
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Thomas Settevik
CHM | Chairman | 64 | - |
Fredrik Thoresen
BRD | Director/Board Member | 44 | - |
Director/Board Member | 60 | - | |
Kjersti Grimsrud
BRD | Director/Board Member | 63 | - |
Director/Board Member | 49 | 31/08/13 | |
Monika Neuman
BRD | Director/Board Member | 59 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 15,422,350 | 8,458,743 ( 54.85 %) | 0 | 54.85 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.99% | 54.91M | |
-1.89% | 12.56B | |
-9.59% | 7.68B | |
+21.82% | 5.18B | |
-1.31% | 5.29B | |
+0.02% | 4.57B | |
-50.89% | 3.29B | |
+6.42% | 2.6B | |
-10.02% | 2.2B | |
-8.29% | 1.79B |
- Stock Market
- Equities
- GENT Stock
- Company Gentian Diagnostics